Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer

Gynecologic Oncology

Volumn 93, Issue 2, 2004, Pages 407-416

  Widschwendter, Andreas ^a   Müller, Hannes M ^a   Hubalek, Michael M ^a   Wiedemair, Annemarie ^a   Fiegl, Heidi ^a   Goebel, Georg ^b   Mueller Holzner, Elisabeth ^a   Marth, Christian ^a   Widschwendter, Martin ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Cervical cancer; DNA methylation; Ovarian cancer; Telomerase

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; AGE DISTRIBUTION; AGED; ANALYTIC METHOD; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METHYLATION; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TELOMERASE; UTERINE CERVICAL NEOPLASMS;

EID: 1942508923     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.01.036     Document Type: Article

References (65)

1. Lundblad V., Szostak J.W. A mutant with a defect in telomere elongation leads to senescence in yeast. Cell. 57:1989;633-643.
2. Larson D.D., Spangler E.A., Blackburn E.H. Dynamics of telomere length variation in tetrahymena thermophila. Cell. 50:1987;477-483.
3. de Lange T. Activation of telomerase in a human tumor. Proc. Natl. Acad. Sci. U. S. A. 91:1994;2882-2885.
4. Marx J. Chromosome ends catch fire. Science. 265:1994;1656-1658.
5. Vaziri H., Dragowska W., Allsopp R.C., Thomas T.E., Harley C.B., Lansdorp P.M. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc. Natl. Acad. Sci. U. S. A. 91:1994;9857-9860.
6. Harley C.B., Vaziri H., Counter C.M., Allsopp R.C. The telomere hypothesis of cellular aging. Exp. Gerontol. 27:1992;375-382.
7. Allsopp R.C., Vaziri H., Patterson C., Goldstein S., Younglai E.V., Futcher A.B.et al. Telomere length predicts replicative capacity of human fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 89:1992;10114-10118.
8. Vaziri H., Schachter F., Uchida I., Wei L., Zhu X., Effros R.et al. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am. J. Hum. Genet. 52:1993;661-667.
9. Hastie N.D., Dempster M., Dunlop M.G., Thompson A.M., Green D.K., Allshire R.C. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 346:1990;866-868.
10. Counter C.M., Avilion A.A., LeFeuvre C.E., Stewart N.G., Greider C.W., Harley C.B.et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11:1992;1921-1929.
11. Counter C.M., Botelho F.M., Wang P., Harley C.B., Bacchetti S. Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes. J. Virol. 68:1994;3410-3414.
12. Feng J., Funk W.D., Wang S.S., Weinrich S.L., Avilion A.A., Chiu C.P.et al. The RNA component of human telomerase. Science. 269:1995;1236-1241.
13. Harrington L., McPhail T., Mar V., Zhou W., Oulton R., Bass M.B.et al. A mammalian telomerase-associated protein. Science. 275:1997;973-977.
14. Nakamura T.M., Morin G.B., Chapman K.B., Weinrich S.L., Andrews W.H., Lingner J.et al. Telomerase catalytic subunit homologs from fission yeast and human. Science. 277:1997;955-959.
15. Kilian A., Bowtell D.D., Abud H.E., Hime G.R., Venter D.J., Keese P.K. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. 6:1997;2011-2019.
16. Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P., Caddle S.D.et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 90:1997;785-795.
17. Beattie T.L., Zhou W., Robinson M.O., Harrington L. Reconstitution of human telomerase activity in vitro. Curr. Biol. 8:1998;177-180.
18. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B.et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 279:1998;349-352.
19. Counter C.M., Meyerson M., Eaton E.N., Ellisen L.W., Caddle S.D., Haber D.A.et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene. 16:1998;1217-1222.
20. Weinrich S.L., Pruzan R., Ma L., Ouellette M., Tesmer V.M., Holt S.E.et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat. Genet. 17:1997;498-502.
21. Shay J.W., Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer. 33:1997;787-791.
22. Zheng P.S., Iwasaka T., Yamasaki F., Ouchida M., Yokoyama M., Nakao Y.et al. Telomerase activity in gynecologic tumors. Gynecol. Oncol. 64:1997;171-175.
23. Yokoyama Y., Takahashi Y., Shinohara A., Lian Z., Tamaya T. Telomerase activity in the female reproductive tract and neoplasms. Gynecol. Oncol. 68:1998;145-149.
24. Nakano K., Watney E., McDougall J.K. Telomerase activity and expression of telomerase RNA component and telomerase catalytic subunit gene in cervical cancer. Am. J. Pathol. 153:1998;857-864.
25. Snijders P.J., van Duin M., Walboomers J.M., Steenbergen R.D., Risse E.K., Helmerhorst T.J.et al. Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Res. 58:1998;3812-3818.
26. Takakura M., Kyo S., Kanaya T., Tanaka M., Inoue M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res. 58:1998;1558-1561.
27. Wisman G.B., Knol A.J., Helder M.N., Krans M., de Vries E.G., Hollema H.et al. Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer. Int. J. Cancer. 91:2001;658-664.
28. Kyo S., Kanaya T., Takakura M., Tanaka M., Yamashita A., Inoue H.et al. Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors. Int. J. Cancer. 80:1999;804-809.
29. Park T.W., Riethdorf S., Riethdorf L., Loning T., Janicke F. Differential telomerase activity, expression of the telomerase catalytic sub-unit and telomerase-RNA in ovarian tumors. Int. J. Cancer. 84:1999;426-431.
30. Cong Y.S., Bacchetti S. Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J. Biol. Chem. 275:2000;35665-35668.
31. Horikawa I., Cable P.L., Afshari C., Barrett J.C. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res. 59:1999;826-830.
32. Takakura M., Kyo S., Kanaya T., Hirano H., Takeda J., Yutsudo M.et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 59:1999;551-557.
33. Wick M., Zubov D., Hagen G. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene. 232:1999;97-106.
34. Poole J.C., Andrews L.G., Tollefsbol T.O. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene. 269:2001;1-12.
35. Guilleret I., Yan P., Grange F., Braunschweig R., Bosman F.T., Benhattar J. Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int. J. Cancer. 101:2002;335-341.
36. Dessain S.K., Yu H., Reddel R.R., Beijersbergen R.L., Weinberg R.A. Methylation of the human telomerase gene CpG island. Cancer Res. 60:2000;537-541.
37. Devereux T.R., Horikawa I., Anna C.H., Annab L.A., Afshari C.A., Barrett J.C. DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res. 59:1999;6087-6090.
38. Guilleret I., Benhattar J. Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. Exp. Cell Res. 289:2003;326-334.
39. Zhang D.K., Ngan H.Y., Cheng R.Y., Cheung A.N., Liu S.S., Tsao S.W. Clinical significance of telomerase activation and telomeric restriction fragment (TRF) in cervical cancer. Eur. J. Cancer. 35:1999;154-160.
40. Terasawa K., Sagae S., Takeda T., Ishioka S., Kobayashi K., Kudo R. Telomerase activity in malignant ovarian tumors with deregulation of cell cycle regulatory proteins. Cancer Lett. 142:1999;207-217.
41. Murakami J., Nagai N., Ohama K., Tahara H., Ide T. Telomerase activity in ovarian tumors. Cancer. 80:1997;1085-1092.
42. Clark G.M., Osborne C.K., Levitt D., Wu F., Kim N.W. Telomerase activity and survival of patients with node-positive breast cancer. J. Natl. Cancer Inst. 89:1997;1874-1881.
43. Hoos A., Hepp H.H., Kaul S., Ahlert T., Bastert G., Wallwiener D. Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer. Int. J. Cancer. 79:1998;8-12.
44. Langford L.A., Piatyszek M.A., Xu R., Schold S.C. Jr., Wright W.E., Shay J.W. Telomerase activity in ordinary meningiomas predicts poor outcome. Hum. Pathol. 28:1997;416-420.
45. Norrback K.F., Dahlenborg K., Carlsson R., Roos G. Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas. Blood. 88:1996;222-229.
46. Zhang W., Piatyszek M.A., Kobayashi T., Estey E., Andreeff M., Deisseroth A.B.et al. Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clin. Cancer Res. 2:1996;799-803.
47. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
48. Bieche I., Nogues C., Paradis V., Olivi M., Bedossa P., Lidereau R.et al. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin. Cancer Res. 6:2000;452-459.
49. Bieche I., Franc B., Vidaud D., Vidaud M., Lidereau R. Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction. Thyroid. 11:2001;147-152.
50. Eads C.A., Lord R.V., Wickramasinghe K., Long T.I., Kurumboor S.K., Bernstein L.et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 61:2001;3410-3418.
51. Eads C.A., Danenberg K.D., Kawakami K., Saltz L.B., Blake C., Shibata D.et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 28:2000;E32.
52. Ramakrishnan S., Eppenberger U., Mueller H., Shinkai Y., Narayanan R. Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res. 58:1998;622-625.
53. Sood A.K., Coffin J., Jabbari S., Buller R.E., Hendrix M.J., Klingelhutz A. p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma. Cancer Biol. Ther. 1:2002;511-517.
54. Ducrest A.L., Amacker M., Mathieu Y.D., Cuthbert A.P., Trott D.A., Newbold R.F.et al. Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity. Cancer Res. 61:2001;7594-7602.
55. Bechter O.E., Eisterer W., Dlaska M., Kuhr T., Thaler J. CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia. Exp. Hematol. 30:2002;26-33.
56. Nomoto K., Maekawa M., Sugano K., Ushiama M., Fukayama N., Fujita S.et al. Methylation status and expression of human telomerase reverse transcriptase mRNA in relation to hypermethylation of the p16 gene in colorectal cancers as analyzed by bisulfite PCR-SSCP. Jpn. J. Clin. Oncol. 32:2002;3-8.
57. Issa J.P., Ahuja N., Toyota M., Bronner M.P., Brentnall T.A. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 61:2001;3573-3577.
58. Jones P.A. The DNA methylation paradox. Trends Genet. 15:1999;34-37.
59. Tanaka T., Iwasa Y., Kondo S., Hiai H., Toyokuni S. High incidence of allelic loss on chromosome 5 and inactivation of p15INK4B and p16INK4A tumor suppressor genes in oxystress-induced renal cell carcinoma of rats. Oncogene. 18:1999;3793-3797.
60. Cerda S., Weitzman S.A. Influence of oxygen radical injury on DNA methylation. Mutat. Res. 386:1997;141-152.
61. Tatsumoto N., Hiyama E., Murakami Y., Imamura Y., Shay J.W., Matsuura Y.et al. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer. Clin Cancer Res. 6:2000;2696-2701.
62. Wang L., Soria J.C., Kemp B.L., Liu D.D., Mao L., Khuri F.R. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clin. Cancer Res. 8:2002;2883-2889.
63. Tang X., Khuri F.R., Lee J.J., Kemp B.L., Liu D., Hong W.K.et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J. Natl. Cancer Inst. 92:2000;1511-1516.
64. Esteller M., Gonzalez S., Risques R.A., Marcuello E., Mangues R., Germa J.R.et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J. Clin. Oncol. 19:2001;299-304.
65. Brabender J., Usadel H., Metzger R., Schneider P.M., Park J., Salonga D.et al. Quantitative o(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin. Cancer Res. 9:2003;223-227.